Photo by Justin Sullivan / Getty
The World Health Organization has recommended that men who have sex with men consider taking daily antiretroviral medicine to prevent HIV, citing climbing infection rates in this group even as incidence has stabilized or fallen in the general population.
The international public health agency’s guidelines follow the U.S. Centers for Disease Control and Prevention recommendation that all Americans at high risk of contracting HIV take the daily preventive medicine, but go one step further by recommending pre-exposure prophylaxis, or PrEP, to all men who have sex with men. The CDC guidelines named high-risk people only, specifically calling out gay men who don’t use condoms among other vulnerable groups.
The daily pill, brand name Truvada, combines two antiretroviral medicines that are also part of a cocktail of drugs used to treat HIV. Recent seminal research, including studies conducted by University of Washington and Fred Hutchinson Cancer Research Center scientists, has shown that PrEP can dramatically reduce risk of HIV infection. The iPrEx study, a 2010 international clinical trial of men who have sex with men, found that daily Truvada use slashed risk of contracting the disease by 99 percent.
“Gay men in particular remain at the highest risk of any high risk group, particularly in the U.S.,” said Dr. Jeanne Marrazzo, HIV prevention expert at UW and Fred Hutch affiliate. “We have incredible biomedical tools in our hands… I think we’ve learned that we haven’t had good luck focusing on the system as it is and interventions as they are.”
Men who have sex with men are at higher risk for HIV in part because the virus is more easily transmitted during anal sex, but also because in many parts of the world, the stigma against homosexuality is so high that gay men and women often don’t receive the same access to health care as their straight counterparts. Marrazzo hopes that the WHO’s guidelines, published in anticipation of next week’s International AIDS Conference in Melbourne, Australia, will help reduce that stigma by acknowledging the health care needs of this HIV-vulnerable population.
Will they take it?
Marrazzo also points out that despite research showing how effective the drugs can be, even participants in HIV prevention studies don’t take their medication daily, or sometimes, even at all. She led a similar study testing Truvada or an antiretroviral vaginal gel in women in Africa and found that the drugs were not effective because so few of the women took them regularly. Adherence in the iPrEx study and some other studies of daily HIV prevention medicine was high enough to show the pills’ power to block infection, but still far from 100 percent.
“Just because the drug is approved, doesn’t mean it will be prescribed. Just because people fill their prescriptions doesn’t mean they will take it, and just because they take it doesn’t mean they will take it regularly and correctly,” Marrazzo said.
Fred Hutch researchers are working on approaches to combat problems with daily dose adherence. The HIV Prevention Trials Network is planning trials of an injectable antiretroviral drug that may only need to be taken every four months. The Microbicide Trials Network is now conducting a clinical trial in several African countries testing a vaginal ring containing preventive drugs that only needs to be replaced every month.
“That takes away some of the user challenges,” said Dr. Jennifer Balkus, an HIV researcher at Fred Hutch who is helping conduct the vaginal ring trial.
Not a magic bullet
Although skipping too many doses of the drug will decrease its effectiveness, the iPrEx study found that even four doses per week reduced infection risk by 96 percent. Marrazzo is concerned about those who take the pill even less frequently but still falsely believe they are protected from HIV infection and thus practice riskier behavior than they would if they weren’t taking the pill.
But other than user error, the pill is very safe. Those starting the drug may have initial mild stomach upset but tend to habituate quickly, Marrazzo said. And despite the fact that the drugs in Truvada are the same used to treat HIV, studies have found that drug resistance from inconsistent use is rare. Of people who skipped doses of the drug and became HIV infected, the vast majority still responded to antiretroviral treatment.
HIV prevention researchers caution that PrEP should not be viewed as an alternative to condoms. Marrazzo points out that syphilis is on the rise among gay men in many regions, including Seattle.
“[Truvada] is not a magic pill,” she said. “It’s a magic pill to prevent HIV, but it’s not a magic pill to keep yourself sexually healthy.”
- A baby thought to be ‘cured’ of HIV shows signs of virus
- Hoping out loud: After years of silence, talk of an HIV cure
- Dr. Jim Kublin brings life lessons to quest for HIV vaccine
Dr. Rachel Tompa is a staff writer at Fred Hutchinson Cancer Research Center. She joined Fred Hutch in 2009 as an editor working with infectious disease researchers and has since written about topics ranging from nanotechnology to global health. She has a Ph.D. in molecular biology from the University of California, San Francisco and a certificate in science writing from the University of California, Santa Cruz. Reach her at firstname.lastname@example.org.
Are you interested in reprinting or republishing this story? Be our guests! We want to help connect people with the information they need. We just ask that you link back to the original article, preserve the author’s byline and refrain from making edits that alter the original context. Questions? Email editor Linda Dahlstrom at email@example.com.